A phase 2 trial of the somatostatin analog pasireotide to prevent GI toxicity and acute GVHD in allogeneic hematopoietic stem cell transplant.
<h4>Background</h4>Allogeneic hematopoietic stem cell transplantation (HCT) is an often curative intent treatment, however it is associated with significant gastrointestinal (GI) toxicity and treatment related mortality. Graft-versus-host disease is a significant contributor to transplan...
Guardado en:
| Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Public Library of Science (PLoS)
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/f83a9f8874344c358e65b574f37f7011 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:f83a9f8874344c358e65b574f37f7011 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:f83a9f8874344c358e65b574f37f70112021-12-02T20:15:46ZA phase 2 trial of the somatostatin analog pasireotide to prevent GI toxicity and acute GVHD in allogeneic hematopoietic stem cell transplant.1932-620310.1371/journal.pone.0252995https://doaj.org/article/f83a9f8874344c358e65b574f37f70112021-01-01T00:00:00Zhttps://doi.org/10.1371/journal.pone.0252995https://doaj.org/toc/1932-6203<h4>Background</h4>Allogeneic hematopoietic stem cell transplantation (HCT) is an often curative intent treatment, however it is associated with significant gastrointestinal (GI) toxicity and treatment related mortality. Graft-versus-host disease is a significant contributor to transplant-related mortality. We performed a phase 2 trial of the somatostatin analog pasireotide to prevent gastrointestinal toxicity and GVHD after myeloablative allogeneic HCT.<h4>Methods</h4>Patients received 0.9mg pasireotide every 12 hours from the day prior to conditioning through day +4 after HCT (or a maximum of 14 days). The primary outcomes were grade 3-4 gastrointestinal toxicity through day 30 and acute GVHD. Secondary outcomes were chronic GVHD, overall survival and relapse free survival at one year. Stool and blood samples were collected from before and after HCT for analyses of stool microbiome, local inflammatory markers, and systemic inflammatory and metabolic markers. Results were compared with matched controls.<h4>Results</h4>Twenty-six patients received pasireotide and were compared to 52 matched contemporaneous controls using a 1-2 match. Grade 3-4 GI toxicity occurred in 21 (81%) patients who received pasireotide and 35 (67%) controls (p = 0.33). Acute GVHD occurred in 15 (58%) patients in the pasireotide group and 28 (54%) controls (p = 0.94). Chronic GVHD occurred in 16 patients in the pasireotide group (64%) versus 22 patients in the control group (42%) (p = 0.12). Overall survival at 1 year in the pasireotide group was 63% (95% CI: 47%,86%) versus 82% (95% CI: 72%, 93%) in controls (log-rank p = 0.006). Relapse-free survival rate at one year was 40% (95% CI: 25%, 65%) in the pasireotide group versus 78% (95% CI: 68%, 91%) in controls (log-rank p = 0.002). After controlling for the effect of relevant covariates, patients in the pasireotide group had attenuated post-HCT loss of microbial diversity. Analysis of systemic inflammatory markers and metabolomics demonstrated feasibility of such analyses in patients undergoing allogeneic HCT. Baseline level and pre-to-post transplant changes in several inflammatory markers (including MIP1a, MIP1b, TNFa, IL8Pro, and IL6) correlated with likelihood of survival.<h4>Conclusions</h4>Pasireotide did not prevent gastrointestinal toxicity or acute GVHD compared to contemporaneous controls. Pasireotide was associated with numerically higher chronic GVHD and significantly decreased OS and RFS compared to contemporaneous controls. Pasireotide may provide a locally protective effect in the stool microbiome and in local inflammation as measured by stool calprotectin, stool beta-defensin, and stool diversity index.Sendhilnathan RamalingamSharareh Siamakpour-ReihaniLauren BohannanYi RenAlexander SibleyJeff ShengLi MaAndrew B NixonJing LyuDaniel C ParkerJames BainMichael MuehlbauerOlga IlkayevaVirginia Byers KrausJanet L HuebnerThomas SpitzerJami BrownJonathan U PeledMarcel van den BrinkAntonio GomesTaewoong ChoiCristina GasparettoMitchell HorwitzGwynn LongRichard LopezDavid RizzieriStefanie SarantopoulosNelson ChaoAnthony D SungPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 16, Iss 6, p e0252995 (2021) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Medicine R Science Q |
| spellingShingle |
Medicine R Science Q Sendhilnathan Ramalingam Sharareh Siamakpour-Reihani Lauren Bohannan Yi Ren Alexander Sibley Jeff Sheng Li Ma Andrew B Nixon Jing Lyu Daniel C Parker James Bain Michael Muehlbauer Olga Ilkayeva Virginia Byers Kraus Janet L Huebner Thomas Spitzer Jami Brown Jonathan U Peled Marcel van den Brink Antonio Gomes Taewoong Choi Cristina Gasparetto Mitchell Horwitz Gwynn Long Richard Lopez David Rizzieri Stefanie Sarantopoulos Nelson Chao Anthony D Sung A phase 2 trial of the somatostatin analog pasireotide to prevent GI toxicity and acute GVHD in allogeneic hematopoietic stem cell transplant. |
| description |
<h4>Background</h4>Allogeneic hematopoietic stem cell transplantation (HCT) is an often curative intent treatment, however it is associated with significant gastrointestinal (GI) toxicity and treatment related mortality. Graft-versus-host disease is a significant contributor to transplant-related mortality. We performed a phase 2 trial of the somatostatin analog pasireotide to prevent gastrointestinal toxicity and GVHD after myeloablative allogeneic HCT.<h4>Methods</h4>Patients received 0.9mg pasireotide every 12 hours from the day prior to conditioning through day +4 after HCT (or a maximum of 14 days). The primary outcomes were grade 3-4 gastrointestinal toxicity through day 30 and acute GVHD. Secondary outcomes were chronic GVHD, overall survival and relapse free survival at one year. Stool and blood samples were collected from before and after HCT for analyses of stool microbiome, local inflammatory markers, and systemic inflammatory and metabolic markers. Results were compared with matched controls.<h4>Results</h4>Twenty-six patients received pasireotide and were compared to 52 matched contemporaneous controls using a 1-2 match. Grade 3-4 GI toxicity occurred in 21 (81%) patients who received pasireotide and 35 (67%) controls (p = 0.33). Acute GVHD occurred in 15 (58%) patients in the pasireotide group and 28 (54%) controls (p = 0.94). Chronic GVHD occurred in 16 patients in the pasireotide group (64%) versus 22 patients in the control group (42%) (p = 0.12). Overall survival at 1 year in the pasireotide group was 63% (95% CI: 47%,86%) versus 82% (95% CI: 72%, 93%) in controls (log-rank p = 0.006). Relapse-free survival rate at one year was 40% (95% CI: 25%, 65%) in the pasireotide group versus 78% (95% CI: 68%, 91%) in controls (log-rank p = 0.002). After controlling for the effect of relevant covariates, patients in the pasireotide group had attenuated post-HCT loss of microbial diversity. Analysis of systemic inflammatory markers and metabolomics demonstrated feasibility of such analyses in patients undergoing allogeneic HCT. Baseline level and pre-to-post transplant changes in several inflammatory markers (including MIP1a, MIP1b, TNFa, IL8Pro, and IL6) correlated with likelihood of survival.<h4>Conclusions</h4>Pasireotide did not prevent gastrointestinal toxicity or acute GVHD compared to contemporaneous controls. Pasireotide was associated with numerically higher chronic GVHD and significantly decreased OS and RFS compared to contemporaneous controls. Pasireotide may provide a locally protective effect in the stool microbiome and in local inflammation as measured by stool calprotectin, stool beta-defensin, and stool diversity index. |
| format |
article |
| author |
Sendhilnathan Ramalingam Sharareh Siamakpour-Reihani Lauren Bohannan Yi Ren Alexander Sibley Jeff Sheng Li Ma Andrew B Nixon Jing Lyu Daniel C Parker James Bain Michael Muehlbauer Olga Ilkayeva Virginia Byers Kraus Janet L Huebner Thomas Spitzer Jami Brown Jonathan U Peled Marcel van den Brink Antonio Gomes Taewoong Choi Cristina Gasparetto Mitchell Horwitz Gwynn Long Richard Lopez David Rizzieri Stefanie Sarantopoulos Nelson Chao Anthony D Sung |
| author_facet |
Sendhilnathan Ramalingam Sharareh Siamakpour-Reihani Lauren Bohannan Yi Ren Alexander Sibley Jeff Sheng Li Ma Andrew B Nixon Jing Lyu Daniel C Parker James Bain Michael Muehlbauer Olga Ilkayeva Virginia Byers Kraus Janet L Huebner Thomas Spitzer Jami Brown Jonathan U Peled Marcel van den Brink Antonio Gomes Taewoong Choi Cristina Gasparetto Mitchell Horwitz Gwynn Long Richard Lopez David Rizzieri Stefanie Sarantopoulos Nelson Chao Anthony D Sung |
| author_sort |
Sendhilnathan Ramalingam |
| title |
A phase 2 trial of the somatostatin analog pasireotide to prevent GI toxicity and acute GVHD in allogeneic hematopoietic stem cell transplant. |
| title_short |
A phase 2 trial of the somatostatin analog pasireotide to prevent GI toxicity and acute GVHD in allogeneic hematopoietic stem cell transplant. |
| title_full |
A phase 2 trial of the somatostatin analog pasireotide to prevent GI toxicity and acute GVHD in allogeneic hematopoietic stem cell transplant. |
| title_fullStr |
A phase 2 trial of the somatostatin analog pasireotide to prevent GI toxicity and acute GVHD in allogeneic hematopoietic stem cell transplant. |
| title_full_unstemmed |
A phase 2 trial of the somatostatin analog pasireotide to prevent GI toxicity and acute GVHD in allogeneic hematopoietic stem cell transplant. |
| title_sort |
phase 2 trial of the somatostatin analog pasireotide to prevent gi toxicity and acute gvhd in allogeneic hematopoietic stem cell transplant. |
| publisher |
Public Library of Science (PLoS) |
| publishDate |
2021 |
| url |
https://doaj.org/article/f83a9f8874344c358e65b574f37f7011 |
| work_keys_str_mv |
AT sendhilnathanramalingam aphase2trialofthesomatostatinanalogpasireotidetopreventgitoxicityandacutegvhdinallogeneichematopoieticstemcelltransplant AT shararehsiamakpourreihani aphase2trialofthesomatostatinanalogpasireotidetopreventgitoxicityandacutegvhdinallogeneichematopoieticstemcelltransplant AT laurenbohannan aphase2trialofthesomatostatinanalogpasireotidetopreventgitoxicityandacutegvhdinallogeneichematopoieticstemcelltransplant AT yiren aphase2trialofthesomatostatinanalogpasireotidetopreventgitoxicityandacutegvhdinallogeneichematopoieticstemcelltransplant AT alexandersibley aphase2trialofthesomatostatinanalogpasireotidetopreventgitoxicityandacutegvhdinallogeneichematopoieticstemcelltransplant AT jeffsheng aphase2trialofthesomatostatinanalogpasireotidetopreventgitoxicityandacutegvhdinallogeneichematopoieticstemcelltransplant AT lima aphase2trialofthesomatostatinanalogpasireotidetopreventgitoxicityandacutegvhdinallogeneichematopoieticstemcelltransplant AT andrewbnixon aphase2trialofthesomatostatinanalogpasireotidetopreventgitoxicityandacutegvhdinallogeneichematopoieticstemcelltransplant AT jinglyu aphase2trialofthesomatostatinanalogpasireotidetopreventgitoxicityandacutegvhdinallogeneichematopoieticstemcelltransplant AT danielcparker aphase2trialofthesomatostatinanalogpasireotidetopreventgitoxicityandacutegvhdinallogeneichematopoieticstemcelltransplant AT jamesbain aphase2trialofthesomatostatinanalogpasireotidetopreventgitoxicityandacutegvhdinallogeneichematopoieticstemcelltransplant AT michaelmuehlbauer aphase2trialofthesomatostatinanalogpasireotidetopreventgitoxicityandacutegvhdinallogeneichematopoieticstemcelltransplant AT olgailkayeva aphase2trialofthesomatostatinanalogpasireotidetopreventgitoxicityandacutegvhdinallogeneichematopoieticstemcelltransplant AT virginiabyerskraus aphase2trialofthesomatostatinanalogpasireotidetopreventgitoxicityandacutegvhdinallogeneichematopoieticstemcelltransplant AT janetlhuebner aphase2trialofthesomatostatinanalogpasireotidetopreventgitoxicityandacutegvhdinallogeneichematopoieticstemcelltransplant AT thomasspitzer aphase2trialofthesomatostatinanalogpasireotidetopreventgitoxicityandacutegvhdinallogeneichematopoieticstemcelltransplant AT jamibrown aphase2trialofthesomatostatinanalogpasireotidetopreventgitoxicityandacutegvhdinallogeneichematopoieticstemcelltransplant AT jonathanupeled aphase2trialofthesomatostatinanalogpasireotidetopreventgitoxicityandacutegvhdinallogeneichematopoieticstemcelltransplant AT marcelvandenbrink aphase2trialofthesomatostatinanalogpasireotidetopreventgitoxicityandacutegvhdinallogeneichematopoieticstemcelltransplant AT antoniogomes aphase2trialofthesomatostatinanalogpasireotidetopreventgitoxicityandacutegvhdinallogeneichematopoieticstemcelltransplant AT taewoongchoi aphase2trialofthesomatostatinanalogpasireotidetopreventgitoxicityandacutegvhdinallogeneichematopoieticstemcelltransplant AT cristinagasparetto aphase2trialofthesomatostatinanalogpasireotidetopreventgitoxicityandacutegvhdinallogeneichematopoieticstemcelltransplant AT mitchellhorwitz aphase2trialofthesomatostatinanalogpasireotidetopreventgitoxicityandacutegvhdinallogeneichematopoieticstemcelltransplant AT gwynnlong aphase2trialofthesomatostatinanalogpasireotidetopreventgitoxicityandacutegvhdinallogeneichematopoieticstemcelltransplant AT richardlopez aphase2trialofthesomatostatinanalogpasireotidetopreventgitoxicityandacutegvhdinallogeneichematopoieticstemcelltransplant AT davidrizzieri aphase2trialofthesomatostatinanalogpasireotidetopreventgitoxicityandacutegvhdinallogeneichematopoieticstemcelltransplant AT stefaniesarantopoulos aphase2trialofthesomatostatinanalogpasireotidetopreventgitoxicityandacutegvhdinallogeneichematopoieticstemcelltransplant AT nelsonchao aphase2trialofthesomatostatinanalogpasireotidetopreventgitoxicityandacutegvhdinallogeneichematopoieticstemcelltransplant AT anthonydsung aphase2trialofthesomatostatinanalogpasireotidetopreventgitoxicityandacutegvhdinallogeneichematopoieticstemcelltransplant AT sendhilnathanramalingam phase2trialofthesomatostatinanalogpasireotidetopreventgitoxicityandacutegvhdinallogeneichematopoieticstemcelltransplant AT shararehsiamakpourreihani phase2trialofthesomatostatinanalogpasireotidetopreventgitoxicityandacutegvhdinallogeneichematopoieticstemcelltransplant AT laurenbohannan phase2trialofthesomatostatinanalogpasireotidetopreventgitoxicityandacutegvhdinallogeneichematopoieticstemcelltransplant AT yiren phase2trialofthesomatostatinanalogpasireotidetopreventgitoxicityandacutegvhdinallogeneichematopoieticstemcelltransplant AT alexandersibley phase2trialofthesomatostatinanalogpasireotidetopreventgitoxicityandacutegvhdinallogeneichematopoieticstemcelltransplant AT jeffsheng phase2trialofthesomatostatinanalogpasireotidetopreventgitoxicityandacutegvhdinallogeneichematopoieticstemcelltransplant AT lima phase2trialofthesomatostatinanalogpasireotidetopreventgitoxicityandacutegvhdinallogeneichematopoieticstemcelltransplant AT andrewbnixon phase2trialofthesomatostatinanalogpasireotidetopreventgitoxicityandacutegvhdinallogeneichematopoieticstemcelltransplant AT jinglyu phase2trialofthesomatostatinanalogpasireotidetopreventgitoxicityandacutegvhdinallogeneichematopoieticstemcelltransplant AT danielcparker phase2trialofthesomatostatinanalogpasireotidetopreventgitoxicityandacutegvhdinallogeneichematopoieticstemcelltransplant AT jamesbain phase2trialofthesomatostatinanalogpasireotidetopreventgitoxicityandacutegvhdinallogeneichematopoieticstemcelltransplant AT michaelmuehlbauer phase2trialofthesomatostatinanalogpasireotidetopreventgitoxicityandacutegvhdinallogeneichematopoieticstemcelltransplant AT olgailkayeva phase2trialofthesomatostatinanalogpasireotidetopreventgitoxicityandacutegvhdinallogeneichematopoieticstemcelltransplant AT virginiabyerskraus phase2trialofthesomatostatinanalogpasireotidetopreventgitoxicityandacutegvhdinallogeneichematopoieticstemcelltransplant AT janetlhuebner phase2trialofthesomatostatinanalogpasireotidetopreventgitoxicityandacutegvhdinallogeneichematopoieticstemcelltransplant AT thomasspitzer phase2trialofthesomatostatinanalogpasireotidetopreventgitoxicityandacutegvhdinallogeneichematopoieticstemcelltransplant AT jamibrown phase2trialofthesomatostatinanalogpasireotidetopreventgitoxicityandacutegvhdinallogeneichematopoieticstemcelltransplant AT jonathanupeled phase2trialofthesomatostatinanalogpasireotidetopreventgitoxicityandacutegvhdinallogeneichematopoieticstemcelltransplant AT marcelvandenbrink phase2trialofthesomatostatinanalogpasireotidetopreventgitoxicityandacutegvhdinallogeneichematopoieticstemcelltransplant AT antoniogomes phase2trialofthesomatostatinanalogpasireotidetopreventgitoxicityandacutegvhdinallogeneichematopoieticstemcelltransplant AT taewoongchoi phase2trialofthesomatostatinanalogpasireotidetopreventgitoxicityandacutegvhdinallogeneichematopoieticstemcelltransplant AT cristinagasparetto phase2trialofthesomatostatinanalogpasireotidetopreventgitoxicityandacutegvhdinallogeneichematopoieticstemcelltransplant AT mitchellhorwitz phase2trialofthesomatostatinanalogpasireotidetopreventgitoxicityandacutegvhdinallogeneichematopoieticstemcelltransplant AT gwynnlong phase2trialofthesomatostatinanalogpasireotidetopreventgitoxicityandacutegvhdinallogeneichematopoieticstemcelltransplant AT richardlopez phase2trialofthesomatostatinanalogpasireotidetopreventgitoxicityandacutegvhdinallogeneichematopoieticstemcelltransplant AT davidrizzieri phase2trialofthesomatostatinanalogpasireotidetopreventgitoxicityandacutegvhdinallogeneichematopoieticstemcelltransplant AT stefaniesarantopoulos phase2trialofthesomatostatinanalogpasireotidetopreventgitoxicityandacutegvhdinallogeneichematopoieticstemcelltransplant AT nelsonchao phase2trialofthesomatostatinanalogpasireotidetopreventgitoxicityandacutegvhdinallogeneichematopoieticstemcelltransplant AT anthonydsung phase2trialofthesomatostatinanalogpasireotidetopreventgitoxicityandacutegvhdinallogeneichematopoieticstemcelltransplant |
| _version_ |
1718374561263648768 |